Therapy Areas: Infectious Diseases
Heron Therapeutics names new director
2 October 2019 -

Heron Therapeutics Inc (Nasdaq: HRTX), a commercial-stage biotechnology company, announced yesterday that it has named Kimberly Manhard as its director.

Manhard has served as executive vice president, Drug Development of Heron since 2016. She has more than 25 years of experience in drug development, regulatory affairs and pharmaceutical operations. From 2014 to 2016, she served as a director of Heron. From 2006 to 2016, she held various positions at Ardea Biosciences Inc, most recently serving as senior vice president of Regulatory Affairs and Development Operations. Earlier she was president of her own consultancy firm, and in 2002, she served as vice president of Regulatory Affairs at Exelixis Inc. Prior to Exelixis, she held various positions at Agouron Pharmaceuticals Inc. She also held various positions at Bristol-Myers Squibb Company in regulatory affairs, where she was responsible for oncology compounds, including Taxol (paclitaxel), and infectious disease compounds, including Videx (didanosine) and Zerit (stavudine).

Barry Quart, PharmD, president and chief executive officer of Heron, said, 'I am pleased to welcome Kimberly to the Heron board. Kimberly has been a key member of our management team over the last 4 years and has been instrumental in driving the drug development and regulatory strategies for our pain and CINV franchises. We look forward to Kimberly's contributions to our board.'



Related Headlines